How this program helps prevent power outages and lowers costs for Arizona businesses
There is a reason the saying, 'when one of us wins, we all win,' has withstood the test of time. In most cases it's true, and Salt River Project's (SRP) Business Demand Response Program was designed with this adage in mind.
This initiative endeavors to simultaneously prevent power outages during the busiest time of year and lower operating costs for Arizona businesses. The result of organizations enrolling? A win-win (for everyone!), and no one knows this more than Grace Klawitter, strategic business account manager for SRP.
No cost with customizable options
A major plus of the SRP Business Demand Response Program — besides being cost-free — is its eligibility versatility. Commercial, institutional, industrial, educational and municipal organizations are all eligible to sign up.
'The program essentially coordinates with these large customers across the Valley to curtail their load during the summer months when we have exceptionally high load on our grid,' Klawitter says.
expand
Klawitter explains that notifications go out to all enrolled in the Business Demand Response Program from SRP's partner Enel. Correspondence comes through via email, phone or SMS, depending on company preferences.
Once companies receive word it's a good time to reduce their energy use, they can do so by eliminating areas such as nonessential lighting, modifying manufacturing processes, adjusting HVAC equipment and more.
Another benefit of the program: It's not a one-size-fits-all option.
'We have different options like partial enrollment, full summer enrollment or even testing the program out for one or two months,' Klawitter says. 'We continue to evolve programs to fit our customers' needs.'
Valuable energy usage insights
To ensure business consumers are getting the most out of the Business Demand Response Program, SRP and Enel collaborate to deliver helpful and insightful tools.
'Depending on the program that (customers) are involved in, they get free, real-time energy use analytics,' Klawitter notes. 'This allows them to dive in hour by hour to understand how machines or processes are working and how this equates to what energy is being used.'
Sustainability and savings
Ultimately, this knowledge empowers businesses to make smarter decisions and further work toward their sustainability goals. 'Customers that may feel like there are not a lot of avenues for them to engage in sustainability initiatives, find that this (program) is fantastic because everybody uses electricity — the greenest energy is the energy you don't use,' Klawitter explains.
Additionally, each participating business is assigned a dedicated strategic energy manager (SEM).
'They are such a fantastic resource and can really help, especially if you have any sort of doubts or obstacles that you might see your facility facing,' Klawitter says.
To learn more about how the SRP Business Demand Response Program works and benefits business customers, visit srp.net/bdr.
Erin Thorburn is an accomplished writer, journalist, photographer and illustrator with over 20 years of experience covering business travel and lifestyle trends in the Southwest. She is the founder and editor of The Best of the Southwest. Additionally, she contributes to publications like AZ Business, AZ Business Leaders, AZRE and Experience AZ magazines.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
The FDA granted Sarepta's rAAVrh74 Viral Vector a Platform Technology Designation
The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy candidate SRP-9003 for limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4), as a platform technology. A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. Future approvals of treatments utilizing the same delivery technology might be accelerated by this designation. Phase III EMERGENE studies for SRP-9003, sometimes referred to as bidridistrogene xeboparvovec, are anticipated to yield data in the middle of 2025, and the FDA may file a proposal later this year. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses the viral vector rAAVrh74, which is produced from rhesus monkeys, in a number of neuromuscular gene therapy initiatives. Only 14% of DMD patients had pre-existing antibodies, which suggests that the vector has low frequencies of these antibodies, which could improve efficacy and lower safety hazards. The FDA has acknowledged the vector's constancy and adaptability, according to Sarepta Therapeutics, Inc. (NASDAQ:SRPT)'s CSO, Louise Rodino-Klapac. The firm can now expedite development throughout its gene therapy pipeline by reusing clinical data, which will cut the timeframe for future therapies of neuromuscular diseases. While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Business Wire
7 days ago
- Business Wire
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & Drug Administration. 'This is one of the first programs to receive platform technology designation and an important recognition by FDA of the reproducibility and adaptability of this technology across multiple therapeutic programs,' said Louise Rodino-Klapac, Ph.D., chief scientific officer and head of research & development, Sarepta. 'The designation underscores and reinforces the consistency of the data we have seen with this AAVrh74 in multiple clinical programs and is yet another example of Sarepta's continued commitment to accelerating the development of potentially transformative treatments for patients with rare genetic diseases like LGMD type 2E/R4.' In keeping with FDA's pursuit of science-driven efficiency, the platform technology designation program is a critical tool that will help support rare disease therapies by streamlining drug development, manufacturing, and review processes for drug product applications by incorporating data from designated technologies. To be eligible for this designation, the technology must be a well-understood and reproducible technology – such as a nucleic acid sequence, molecular structure, mechanism of action, delivery method, vector, or a combination of any such technologies – and can support the development of multiple drugs or biologics. A platform is also eligible for consideration if it is incorporated in an approved drug and preliminary evidence demonstrates that the technology has the potential to be incorporated in or utilized by more than one drug without an adverse effect on quality, manufacturing, or safety, including using the same manufacturing process. Once granted, the designation enables sponsors to leverage prior data from the platform to support investigational new drug applications (INDs), new drug applications (NDAs) or biologic license applications (BLAs). About SRP-9003 (bidridistrogene xeboparvovec) SRP-9003 (bidridistrogene xeboparvovec) is an investigational gene therapy designed to be systemically and robustly delivered to skeletal, diaphragm and cardiac muscle, making it an ideal candidate to treat neuromuscular diseases. SRP-9003 is intended to deliver a full-length beta-sarcoglycan transgene and uses the MHCK7 promoter, chosen for its ability to robustly express in the heart which is critically important for patients with limb-girdle muscular dystrophy Type 2E (LGMD2E), also known as beta-sarcoglycanopathy and LGMDR4, many of whom die from pulmonary or cardiac complications. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, product candidates, the potential benefits of AAVrh74 and the potential for our therapies to be transformative for patients living with rare diseases. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results; success in clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; we may not be able to comply with all FDA requests in a timely manner or at all; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulatory decisions by, and any halts imposed by, regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.
Miami Herald
29-05-2025
- Miami Herald
VIEWPOINT: Brenmiller Energy's CBO on Why Thermal Energy Storage is Critical to Nuclear's Second Act
TEL AVIV, IL / ACCESS Newswire / May 28, 2025 / Over the last few weeks, it's become increasingly clear that Europe is rethinking its long-held stance on nuclear power. Countries like Denmark, Germany, and Spain are pivoting from prior bans and phase-outs toward the reintegration of nuclear energy into their decarbonization agendas. The May 27th CNBC report confirmed what many of us in the industry have been anticipating: energy independence and long-term grid stability are now taking priority over political resistance to legacy nuclear policies. This isn't just a European trend. In the United States, the nuclear conversation is also heating up. Just last week, the Trump administration issued two executive orders to accelerate the development and deployment of nuclear energy infrastructure. One order clears regulatory red tape for advanced nuclear projects, while the other earmarks new federal support for the deployment of small modular reactors (SMRs) in rural and off-grid communities. Taken together, they signal a dramatic shift toward treating nuclear not as an ideological debate but as a national security and resilience imperative. As Chief Business Officer of Brenmiller Energy, I view this shift not just as a reversal of prior sentiment but as a turning point for how the world will design and connect energy systems for the next generation. At the center of this new approach is flexibility - a trait nuclear energy alone doesn't possess. However, it can with thermal energy storage (TES) in its supporting cast. The Flexibility Problem: Why Baseload Isn't Enough Nuclear power excels in providing a consistent baseload of energy. But that strength becomes a liability in today's dynamic energy market. Grids increasingly require responsive assets that can ramp up or down in real time to match volatile demand curves shaped by solar and wind variability. This is where TES, particularly our bGen™ system, comes into play. At Brenmiller Energy, we've long understood the strategic value of decoupling energy generation from energy consumption. Our thermal storage technology enables energy - whether from renewable sources or nuclear reactors - to be stored as heat and dispatched when needed, 24/7/365. This unique service isn't theoretical. Our commercial partnerships and pilot projects, including with ENEL, the largest European energy provider by customer count, Tempo Beverage in Israel, Entelios in Germany, and others, has already proven the reliability and scalability of bGen™ for industrial energy users in a real-world setting. What ENEL saw in the flexible thermal application, and what many utilities are now beginning to understand, is that TES acts as a critical interface between legacy infrastructure and the demands of next-generation systems. As Europe advances its green hydrogen and renewable integration targets, policymakers are finally confronting the hidden costs of intermittency and grid inflexibility. Nuclear offers dependable generation but not agility. That's where TES fills the gap. It manages the mismatches between supply and demand, mitigating the risks of repeating the very same rigidity issues that led to nuclear phase-outs in the first place. From Concept to Commercial Readiness Consider our recent milestone in Spain: the SolWinHy Cádiz project, an off-grid, green methanol production facility, secured €25 million in funding, with €7 million explicitly allocated to Brenmiller's bGen™ thermal storage. Why? Because in an island-mode operation that's disconnected from the national grid, energy flexibility isn't a luxury. It's a requirement. That same logic applies to nuclear. Advanced nuclear reactors are smaller, modular, and more widely deployable. But without a load-following mechanism, they still suffer from the same mismatch between generation capacity and real-time grid needs. TES provides that mechanism. And serving that need isn't a far-off vision. With over $40 million in deployable bGen™ infrastructure and a pipeline of global projects underway, Brenmiller Energy is uniquely positioned and able to meet this moment. We believe that with the right supporting technology, like bGen, the nuclear revival on both sides of the Atlantic doesn't need to clash with the renewable agenda. The two can - and must - work in tandem. However, this will only happen with enabling technologies like TES, which can seamlessly connect these assets into a cohesive, responsive, and resilient energy network. At Brenmiller Energy, we're not just watching the shift - we're helping to power it. As policy evolves, so too must infrastructure. Nuclear energy without flexibility is a missed opportunity. The most excellent news during nuclear's second chance is that legacy rigidity is no longer a concern. With bGen TES technology included to complement, nuclear gets a foundational building block of the new energy economy. And as we've demonstrated with ENEL, SolWinHy, Tempo Beverage, and others, we're not just theorizing; we're putting our innovative assets into practice. We're proud to say that, as of now, we're the only known TES provider who can. By Doron BrenmillerChief Business Officer, Brenmiller Energy (NASDAQ:BNRG) About bGen™ bGen™ ZERO is Brenmiller's TES system, which converts electricity into heat to power sustainable industrial processes at a price that is competitive with natural gas. The bGen™ ZERO charges by capturing low-cost electricity from renewables or the grid and stores it in crushed rocks. It then discharges steam, hot water, or hot air on demand according to customer requirements. The bGen™ ZERO also supports the development of utility-scale renewables by providing critical flexibility and grid-balancing capabilities. bGen™ ZERO was named among TIME's Best Inventions of 2023 in the Green Energy category and won Gold in the Energy Storage and Management category at the 2025 Edison Awards. About Brenmiller Energy Ltd. Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller's patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers' needs. The most experienced thermal battery developer on the market, Brenmiller operates the world's only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company's website at and follow the company on X and LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the company is using forward-looking statements in this press release when it discusses: that the Company's bGen™ system installation at Purchase College will reduce 550 metric tons of CO2 emissions annually; that TES modularity enables flexible and efficient deployment across diverse infrastructure; and that as more public entities prioritize net-zero transitions, scalable and proven solutions like our bGen™ can provide a suitable solution. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain crucial factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company's results include, but are not limited to: the company's planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the company, including those set forth in the Risk Factors section of the company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 4, 2025, which is available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact: investors@ SOURCE: Brenmiller Energy
